Lacnotuzumab
Product Specifications
UNSPSC Description
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2].
Target Antigen
c-Fms
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/lacnotuzumab.html
Solubility
H2O
Smiles
[Lacnotuzumab]
References & Citations
[1]Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):106-115.|[2]Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99368/Lacnotuzumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99368/
Clinical Information
Phase 2
CAS Number
1831128-32-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ARP36270_P050-FITC 100 µL
FLJ33706 Antibody - C-terminal region: FITC (ARP36270_P050-FITC)
Ask
View Details